drugset / Trial / NCT00730145

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

NCT00730145

Phase 1 Completed 8 enrolled Pfizer
Non-randomizedSingle-groupOpen-label

Summary

1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.

Timeline

Start
2008-09
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IMAGABALIN Other / unclassified 50 mg Oral

Indications

No indication recorded.